BusinessWire IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell… Business Wire News Nov 11, 2022 Approval based on POSEIDON Phase III trial results, which showed significant survival benefit with a limited course of IMJUDO added to IMFINZI and chemotherapy WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI® (durvalumab) in…